【Initial】 Yusen Jianheng completed a round of financing of 200 million yuan to develop innovative drugs for oncology and autoimmunity

Recently, Yusen Jianheng Biopharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Yusen Jianheng") announced the completion of more than 200 million yuan of Series A financing. This round of financing was led by Shenzhen Sharing Investment, followed by Zhangjiang Haoheng and Yingke Capital, and the original shareholders continued to participate in this round of investment. The proceeds will be used to conduct and accelerate domestic and international clinical trials of UA007 and UA021, small molecule drug development with multiple new targets, and the development of specific dual antibody drugs.

Huang, co-founder of the lead investor sharing investment and head of the healthcare fund, said: "It is an honor to participate in the Series A financing of Yusen Jianheng. Yusen Jianheng has established a relatively complete R & D team with complementary professional and resources, focusing on the field of new generation of tumors and autoimmunity, and has broad market development prospects. The progress of the project has become gradient, and the indications are differentiated, and the research and development is sustainable, and it is expected that the continuous and rapid development of Yusen Jianheng in the later period is expected. ”

Wang Wenjie, deputy general manager of Zhangjiang Haoheng, said: "The team of Yusen Jianheng has many years of experience in the research and development of new drugs at home and abroad, and has a layout for specific disease spectrum in the macromolecular pipeline and the small molecule pipeline, and the pipeline of the product under development has formed a differentiated layout, and the positioning of the product is oriented to the global market. Zhangjiang Fufeng Fund managed by Zhangjiang Haoheng is a science and technology innovation sub-fund under the Pudong Science and Technology Innovation Fund of Funds, with Zhangjiang Hi-Tech as the cornerstone investor, and will fully support the entrepreneurship and development of Yusen Jianheng in Zhangjiang Science City. ”

The three co-founders, Dr. Jinsong Li, Dr. Tao Hu and Dr. Peng Shengbin, thanked the investors for their recognition and support of the company's team and pipeline. Chairman Li Jinsong said: "Thanks to the recognition of the company's concept and team by investors, Yusen Jianheng aims to become a first-class innovative drug research and development company; in the future, the company will focus on establishing an efficient translational medicine research and development system in the three aspects of international market, organizational structure, cost and efficiency, and develop innovative drugs with controllable costs for the global large variety of markets." ”

About Yumori Kenheng

Yusen Kenheng is an innovative drug company dedicated to the development of First-in-class/Best-in-class drugs, focusing on cancer and autoimmune diseases, targeting difficult drug targets and key oncogenes, and the R&D pipeline includes small molecule targeted drugs, recombinant proteins and mono/double antibody drugs. The company's core team has served as an executive in multinational pharmaceutical companies and domestic CRO leading enterprises, and has rich experience in the field of innovative drug research and development. At present, the company's UA007 project has conducted a clinical phase II (prevention and treatment of CID) and a clinical phase I study (treatment of acute gout) in China. The small molecule-targeted drug UA021 for autoimmune diseases is in the IND enabling phase and is expected to conduct global clinical trials in 2022.

About sharing investments

Founded in Shenzhen in 2007, Sharing Investment has more than 200 investment enterprises and currently has more than RMB8 billion under management. Sharing Investment since 2010 began to lay out investment in the medical field, with precision medicine as the main line, benchmarking the height of global research and development, adapting to the needs of domestic emerging markets, focusing on biotechnology, new drug research and development, new medical services, cutting-edge medical devices in the four major areas, currently managing four medical and health theme funds, with an independent professional medical investment team of 12 people, with rich investment experience and deep professional background, has invested in more than 80 medical projects, the total scale of medical funds is nearly 4.5 billion yuan. Major investment cases include: BGI Genomics (300676. SZ), Mei Nian Da Health (002044. SZ), Buchang Pharmaceutical (603858. SH), Zejing Pharmaceutical (688266.SH), Panshengzi (GTH. US), Tianchen Medical (688013. SH), Maxcope Medicine (301033. SZ), Haiyou New Material (688680. SH), Novizan (688105. SH), Bepsys (301080. SZ), Carbon Cloud Intelligence, Concentric Medical, Fei peng biological, Huajin Pharmaceutical, Haichang Pharmaceutical, Gusen Pharmaceutical, Polar Orange Dental, Okada, Binhui Biological, etc.

About Zhang Jiang Haoheng

Zhangjiang Haoheng is an equity investment management company initiated and established by Zhangjiang Hi-Tech in 2019, with a fund size of 2 billion yuan in the first phase, focusing on scientific and technological innovation enterprises in the fields of integrated circuits, biomedicine and medical devices, new generation information technology, intelligent manufacturing and other fields and industries. The company is based on the core industries of Zhangjiang Science City, focusing on "hard technology" industries and industries, using capital to help scientific and technological innovation, and relying on the rich industrial ecology of Zhangjiang Hi-Tech, drawing on various innovative elements and resources, providing enterprises with diversified support and services such as space products, talent introduction, and industrial policy support.

About Pacific Century Capital

In just 10 years, Yingke Capital has become one of the top investment institutions in China, with an asset management scale of more than 50 billion yuan and 90% of the entrusted management funds from financial institutions and state-owned enterprises. With the mission of "discovering the power of economic progress", the company focuses on scientific and technological innovation enterprises that conform to the national development strategy and have key core technologies, locks in the core tracks of biomedicine and hard technology, adheres to the dual strategy of "biomedical industry investment + life science industry holding", accurately lays out more than 100 leading enterprises in the whole industrial chain of biomedicine, and is known as the entrance-level and platform-type investment institution for capital to enter the biomedical track.